About
Tumor Phenotype Modification
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyBoston & New England
Clinical Trials (50)
View allTotal Trials
50
As Lead Sponsor
30
As Collaborator
20
Total Enrollment
3,142
By Phase
PHASE3: 1PHASE1: 18PHASE1/PHASE2: 10PHASE2: 19EARLY_PHASE1: 1
By Status
COMPLETED: 24TERMINATED: 9RECRUITING: 8ACTIVE_NOT_RECRUITING: 5WITHDRAWN: 2NOT_YET_RECRUITING: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline49 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT07211958Lead Sponsor
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
PHASE3Not yet recruiting
468 participants
Started: Dec 31, 2025 · Completed: Jan 31, 2031
NCT06313437Collaborator
Revumenib in Combination With 7+3 + Midostaurin in AML
PHASE1Recruiting
22 participants
Started: Dec 6, 2024 · Completed: Mar 2, 2027
NCT06284486Collaborator
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
PHASE1/PHASE2Recruiting
8 participants
Started: Sep 23, 2024 · Completed: Dec 30, 2028
NCT06229912Collaborator
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
PHASE2Recruiting
40 participants
Started: Jun 4, 2024 · Completed: Dec 1, 2028
NCT06226571Lead Sponsor
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
PHASE1Recruiting
76 participants
Started: May 21, 2024 · Completed: Feb 28, 2027
Locations (1)
Headquarters
Waltham, MA, United States
Map
Loading map...